JP2017527567A - 癌の治療のための注射製剤 - Google Patents

癌の治療のための注射製剤 Download PDF

Info

Publication number
JP2017527567A
JP2017527567A JP2017512976A JP2017512976A JP2017527567A JP 2017527567 A JP2017527567 A JP 2017527567A JP 2017512976 A JP2017512976 A JP 2017512976A JP 2017512976 A JP2017512976 A JP 2017512976A JP 2017527567 A JP2017527567 A JP 2017527567A
Authority
JP
Japan
Prior art keywords
formulation
cancer
compound
acid
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527567A5 (enExample
Inventor
ジェームス オルハヴァ，エドワード
ジェームス オルハヴァ，エドワード
ドヴレトグロウ，アンゲロス
ヴァルト，スティーブ
リーレンダー，ブルース
Original Assignee
エピザイム インコーポレイテッド
エピザイム インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピザイム インコーポレイテッド, エピザイム インコーポレイテッド filed Critical エピザイム インコーポレイテッド
Publication of JP2017527567A publication Critical patent/JP2017527567A/ja
Publication of JP2017527567A5 publication Critical patent/JP2017527567A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017512976A 2014-09-17 2015-09-17 癌の治療のための注射製剤 Pending JP2017527567A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051904P 2014-09-17 2014-09-17
US62/051,904 2014-09-17
PCT/US2015/050785 WO2016044649A1 (en) 2014-09-17 2015-09-17 Injectable formulations for treating cancer

Publications (2)

Publication Number Publication Date
JP2017527567A true JP2017527567A (ja) 2017-09-21
JP2017527567A5 JP2017527567A5 (enExample) 2018-10-25

Family

ID=55533871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512976A Pending JP2017527567A (ja) 2014-09-17 2015-09-17 癌の治療のための注射製剤

Country Status (6)

Country Link
US (3) US20170290765A1 (enExample)
EP (1) EP3193879A4 (enExample)
JP (1) JP2017527567A (enExample)
AU (1) AU2015317509A1 (enExample)
CA (1) CA2960287A1 (enExample)
WO (1) WO2016044649A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039839A1 (en) 2012-09-06 2014-03-13 Epizyme, Inc. Method of treating leukemia
EP2968387A4 (en) 2013-03-15 2017-04-05 Epizyme, Inc. Methods of synthesizing substituted purine compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
JP2006199588A (ja) * 2003-05-06 2006-08-03 Senju Pharmaceut Co Ltd オキサゾリジノン誘導体含有水性液剤
JP2013544846A (ja) * 2010-12-03 2013-12-19 エピザイム，インコーポレイティド 置換プリン及び７‐デアザプリン化合物
WO2014039839A1 (en) * 2012-09-06 2014-03-13 Epizyme, Inc. Method of treating leukemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2149150C (en) * 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
WO2008088816A1 (en) * 2007-01-18 2008-07-24 Pgxhealth, Llc Adenosine derivative formulations for medical imaging
RU2470636C2 (ru) * 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
EP2629775A4 (en) * 2010-10-18 2014-06-11 Dainippon Sumitomo Pharma Co INJECTABLE FORMULATION WITH DELAYED RELEASE
GB201021267D0 (en) * 2010-12-15 2011-01-26 Reckitt Benckiser Healthcare Int Ltd Novel pharmaceutical formulation
US20150284422A1 (en) * 2012-08-10 2015-10-08 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
CA2894220A1 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. Dot1l inhibitors for use in the treatment of leukemia
JP2016513699A (ja) * 2013-03-15 2016-05-16 エピザイム，インコーポレイティド 癌の治療のための注射製剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
JP2006199588A (ja) * 2003-05-06 2006-08-03 Senju Pharmaceut Co Ltd オキサゾリジノン誘導体含有水性液剤
JP2013544846A (ja) * 2010-12-03 2013-12-19 エピザイム，インコーポレイティド 置換プリン及び７‐デアザプリン化合物
WO2014039839A1 (en) * 2012-09-06 2014-03-13 Epizyme, Inc. Method of treating leukemia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EXPERT OPIN.DRUG DELIV., vol. 2(2), JPN6017035902, 2005, pages 335 - 351, ISSN: 0004056907 *

Also Published As

Publication number Publication date
EP3193879A1 (en) 2017-07-26
US20190388335A1 (en) 2019-12-26
CA2960287A1 (en) 2016-03-24
WO2016044649A1 (en) 2016-03-24
AU2015317509A1 (en) 2017-03-16
EP3193879A4 (en) 2018-05-16
US20210251887A1 (en) 2021-08-19
US20170290765A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
AU2017273726B2 (en) Use of EZH2 inhibitors for treating cancer
US20220160721A1 (en) Methods of treating cancer
JP2023071905A (ja) 癌を処置するためのｅｚｈ２阻害剤
US20230181549A1 (en) Use of ezh2 inhibitors for treating cancer
JP6538656B2 (ja) ５’−ヌクレオチダーゼ阻害剤およびその治療的使用
AU2018206764A1 (en) Method of treating leukemia
AU2013361076A1 (en) DOT1 L inhibitors for use in the treatment of leukemia
WO2014100662A1 (en) Dot1 l inhibitors for use in the treatment of leukemia
JP2016517426A (ja) 置換プリン化合物の合成方法
US20210353661A1 (en) Injectable formulations for treating cancer
US20210251887A1 (en) Injectable formulations for treating cancer
US20180028552A1 (en) Combination therapy for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180914

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200204